Terms: = Colorectal cancer AND RNF43, DKFZp781H02126, 54894, Q68DV7, URCC, RNF124, MGC125630, FLJ20315, DKFZp781H0392 AND Treatment
30 results:
1. Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer.
Ozeki H; Shimada Y; Nakano M; Kondo S; Ohashi R; Miwa Y; Yamai D; Matsumoto A; Abe K; Tajima Y; Ichikawa H; Sakata J; Takii Y; Sugai M; Nagai T; Ling Y; Okuda S; Wakai T
Hum Pathol; 2024 Mar; 145():71-79. PubMed ID: 38423222
[TBL] [Abstract] [Full Text] [Related]
2. Association of rnf43 Genetic Alterations With BRAF
Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A
JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466
[TBL] [Abstract] [Full Text] [Related]
3. DNA Mutational Profiling in Patients With colorectal cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
[TBL] [Abstract] [Full Text] [Related]
4. Predictive Impact of
Moretto R; Germani MM; Ros J; Daniel F; Ghelardi F; Vetere G; Giordano M; Toledo RA; Bergamo F; Randon G; Elez E; Lonardi S; Pietrantonio F; Vignali P; Rossini D; Matito J; Ugolini C; Fontanini G; Masi G; Cremolini C
JCO Precis Oncol; 2023 Sep; 7():e2300255. PubMed ID: 37797285
[TBL] [Abstract] [Full Text] [Related]
5. treatment of
Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
[TBL] [Abstract] [Full Text] [Related]
6. Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.
Huang W; Li W; Xu N; Li H; Zhang Z; Zhang X; He T; Yao J; Xu M; He Q; Guo L; Zhang S
Cancer Med; 2023 May; 12(9):10187-10198. PubMed ID: 37096801
[TBL] [Abstract] [Full Text] [Related]
7. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
Ye LF; Huang ZY; Chen XX; Chen ZG; Wu SX; Ren C; Hu MT; Bao H; Jin Y; Wang F; Wang FH; Du ZM; Wu X; Ju HQ; Shao Y; Li YH; Xu RH; Wang DS
Drug Resist Updat; 2022 Dec; 65():100883. PubMed ID: 36202008
[TBL] [Abstract] [Full Text] [Related]
8. rnf43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF
Elez E; Ros J; Fernández J; Villacampa G; Moreno-Cárdenas AB; Arenillas C; Bernatowicz K; Comas R; Li S; Kodack DP; Fasani R; Garcia A; Gonzalo-Ruiz J; Piris-Gimenez A; Nuciforo P; Kerr G; Intini R; Montagna A; Germani MM; Randon G; Vivancos A; Smits R; Graus D; Perez-Lopez R; Cremolini C; Lonardi S; Pietrantonio F; Dienstmann R; Tabernero J; Toledo RA
Nat Med; 2022 Oct; 28(10):2162-2170. PubMed ID: 36097219
[TBL] [Abstract] [Full Text] [Related]
9. Exome sequencing revealed comparable frequencies of rnf43 and BRAF mutations in Middle Eastern colorectal cancer.
Siraj AK; Bu R; Masoodi T; Parvathareddy SK; Iqbal K; Al-Haqawi W; Al-Dossari H; Azam S; Qadri Z; Annaiyappanaidu P; Al-Dayel F; Al-Kuraya KS
Sci Rep; 2022 Jul; 12(1):13098. PubMed ID: 35907983
[TBL] [Abstract] [Full Text] [Related]
10. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
Principe DR
Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of rnf43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
[TBL] [Abstract] [Full Text] [Related]
12. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated colorectal cancer.
Rajamäki K; Taira A; Katainen R; Välimäki N; Kuosmanen A; Plaketti RM; Seppälä TT; Ahtiainen M; Wirta EV; Vartiainen E; Sulo P; Ravantti J; Lehtipuro S; Granberg KJ; Nykter M; Tanskanen T; Ristimäki A; Koskensalo S; Renkonen-Sinisalo L; Lepistö A; Böhm J; Taipale J; Mecklin JP; Aavikko M; Palin K; Aaltonen LA
Gastroenterology; 2021 Aug; 161(2):592-607. PubMed ID: 33930428
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with colorectal cancer.
Salem ME; Battaglin F; Goldberg RM; Puccini A; Shields AF; Arguello D; Korn WM; Marshall JL; Grothey A; Lenz HJ
Oncologist; 2020 May; 25(5):404-413. PubMed ID: 31848314
[TBL] [Abstract] [Full Text] [Related]
14. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.
Guadagni S; Fiorentini G; De Simone M; Masedu F; Zoras O; Mackay AR; Sarti D; Papasotiriou I; Apostolou P; Catarci M; Clementi M; Ricevuto E; Bruera G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):205-219. PubMed ID: 31620896
[TBL] [Abstract] [Full Text] [Related]
15. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
16. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract] [Full Text] [Related]
17. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract] [Full Text] [Related]
18. Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Katoh M; Katoh M
Int J Mol Med; 2017 Sep; 40(3):587-606. PubMed ID: 28731148
[TBL] [Abstract] [Full Text] [Related]
19. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
[TBL] [Abstract] [Full Text] [Related]
20. rnf43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
[TBL] [Abstract] [Full Text] [Related]
[Next]
